JACC-Heart Failure

Papers
(The H4-Index of JACC-Heart Failure is 43. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)
ArticleCitations
Curing Ourselves of Toxic Positivity for Hospital-at-Home257
Wearable Remote Patient Monitoring Devices133
Reply115
Reply106
Examination of Initiation Patterns for Sacubitril/Valsartan Among Older Adults With HFrEF in the United States102
CHIEF Effects of Sodium Glucose Co-Transporter Inhibitors on Health-Related Quality of Life in Heart Failure101
Long-Term Effects of Sotatercept on Right Ventricular Function93
Developing a System for Best Performance for Cardiac Transplantation89
Reply88
Reply84
Editorial Board83
Full issue PDF81
Clinical Inertia Disturbs the Harmonious Treatment of Heart Failure76
Racial and Genetic Differences in Presentation of Transthyretin Amyloid Cardiomyopathy With Impaired Left Ventricular Function75
Recognizing the Top Reviewers and Top Authors of JACC: Heart Failure73
Opportunities for Change in Home Health Care in Heart Failure72
Associations Between Urinary Metal Levels and Incident Heart Failure70
Unique Proteomic Signatures in Human Anthracycline-Induced Dilated Cardiomyopathy70
Correction70
Clinical Implications of the P.V142I TTR Variant67
Geographic Variation in the Quality of Heart Failure Care Among U.S. Veterans65
Myeloperoxidase in Heart Failure With Preserved Ejection Fraction65
Eating to Prevent Both Heart and Planetary Failure64
Vericiguat and Cardiovascular Outcomes in Heart Failure by Baseline Diabetes Status63
Pulmonary Artery Catheter Timing and Outcomes for Patients With Cardiogenic Shock61
Revisiting ICD Therapy for Primary Prevention59
Contemporary Trends in Heart Failure Mortality58
Acute Decompensated Heart Failure in the Setting of Acute Coronary Syndrome56
Design and Baseline Characteristics of STEP-HFpEF Program Evaluating Semaglutide in Patients With Obesity HFpEF Phenotype56
Sodium Zirconium Cyclosilicate in HFrEF and Hyperkalemia56
Growth Hormone Replacement Therapy in Heart Failure With Reduced Ejection Fraction56
Early U.S. Heart Transplant Experience With Normothermic Regional Perfusion Following Donation After Circulatory Death54
Tachycardia and Atrial Fibrillation-Related Cardiomyopathies53
Predictors of Incident Heart Failure Diagnosis Setting49
Challenges Addressing Prognosis in Advanced Heart Failure47
The Impact of Social Determinants of Health on Timely Detection in Transthyretin Cardiac Amyloidosis47
Effect of Sotagliflozin on Early Mortality and Heart Failure-Related Events45
Inhibiting Both Neprilysin and Phosphodiesterase Type 945
Challenges in Cardiomyopathy Gene Therapy Clinical Trial Design44
Heart Failure With Preserved Ejection Fraction44
NT-proBNP43
Body Composition and Survival in Patients With Heart Failure43
Framework for Analytical Validation of DHT-Based Actigraphy and Signal Measures in HF Trials43
Effects of Acute Phase Intensive Exercise Training in Patients With Acute Decompensated Heart Failure43
0.19767999649048